M2 Pharma - Policy and Regulations

Medidata Partners with CTI for Remote Source Review of Clinical Trials in Response to COVID-19

8 July 2020 - - US-based contract research organization CTI Clinical Trial and Consulting Services will use US-based clinical trial solutions provider Medidata's Remote Source Review to power rem...

LYNPARZA Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer

8 July 2020 - - LYNPARZA has been approved in the European Union as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinom...

FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients with a Severe form of Scleroderma

8 July 2020 - - The US Food and Drug Administration has approved US-based biotechnology company Talaris Therapeutics, Inc's Investigational New Drug application for the evaluation of Talaris'...

Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

8 July 2020 - - Swiss RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and UAE-based rare disease company taiba Middle East have formed a Distribution Agreement for both ONP...

ViralClear Pharmaceuticals Partners with Albany Molecular Research on the Manufacture of Merimepodib Active Pharmaceutical Ingredient in Development for the Potential Treatment of COVID-19

8 July 2020 - - US-based ViralClear Pharmaceuticals, Inc, supported by contract research, development, and manufacturing organisation Albany Molecular Research Inc is undertaking research to...

Ridgeback Biotherapeutics Starts Enrollment for Phase 2 Trial of Potential COVID-19 Treatment

8 July 2020 - - US-based Ridgeback Biotherapeutics has started enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801, the company said.

The new trial will be conducted u...